ClinicalTrials.gg

Program

Immunoconjugates

Also written as “Antibody-drug conjugate (ADC)”, “Antibody-Drug Conjugate” and “Dose Escalation, MEDI2228, ADC (antibody drug conjugate)”.

Its studies are mostly in Sarcoma · Neoplasms · Multiple Myeloma, led by 3 companies.

Furthest: phase 2, since Jan 16, 20253 company-led studies, 2 open or runningNext primary completion: Feb 27, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Adcendo ApS11 open or runningphase 2since Jan 16, 2025Jan 16, 2025Feb 27, 2029phase 2 · NCT06797999
AstraZeneca10 open or runningphase 1since Mar 17, 2018Mar 17, 2018none ahead
MBrace Therapeutics11 open or runningphase 2since Aug 1, 2023Aug 1, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 17, 2018First study: phase 1 study in Multiple MyelomaNew to AstraZenecaAstraZeneca · NCT03489525 · 107 enrolled · United States, Australia, Greece and more
  2. Aug 1, 2023MBrace Therapeutics's first study: phase 2 study in NeoplasmsNew to MBrace TherapeuticsMBrace Therapeutics · NCT06014658 · 130 planned · United States
  3. Jan 16, 2025Adcendo ApS's first study: phase 2 study in SarcomaNew to Adcendo ApSAdcendo ApS · NCT06797999 · 270 planned · United States, Belgium, France and more

Ahead

  1. Feb 27, 2029Primary completion: phase 2 study in SarcomaAdcendo ApS · NCT06797999

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06797999Sarcoma · United States, Belgium, France and more2RecruitingAdcendo ApSFeb 27, 2029270
NCT06014658Neoplasms · United States2RecruitingMBrace TherapeuticsJul 2026130
NCT03489525Multiple Myeloma · United States, Australia, Greece and more1CompletedAstraZenecaMar 21, 2022107

How it is read

Names in the registry

  • “Antibody-drug conjugate (ADC)”, 1 entry
  • “Antibody-Drug Conjugate”, 1 entry
  • “Dose Escalation, MEDI2228, ADC (antibody drug conjugate)”, 1 entry
  • “Dose Expansion, MEDI2228, ADC (antibody drug conjugate)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.